Abstract
Background: Atherosclerosis is the leading cause of death and morbidity throughout industrialized nations, accounting for one-fifth of all deaths globally. Exosomes are bi-lipid membranous vesicles containing protein, lipid and nucleic acid contents that are released from the cells via the endolysosomal pathway. Exosomes are derived from several cells including macrophages, dendritic cells, platelets as well as human serum.
Methods: In this review, an overview of recent advances, the evidence for the role of exosomes and exosomederived microRNAs (miRNAs) in atherosclerosis are provided.
Results: Recent evidence has shown that exosomes derived from the cells mentioned above are involved in atherosclerosis, whose secretion appears to be regulated by various natural and experimental stimuli, physiological and pathological processes.
Conclusion: Exosomes are now accepted as specifically secreted vesicles that enable intercellular communications and have become exponentially interesting to be used as the possible relevant biomarkers in disease development such as cadiovascular disease, particular in atherosclerosis in addition to their minimally invasive clinical diagnosis.
Keywords: Atherosclerosis, exosome, microRNA, MMP, CVD, vesicles.
Current Pharmaceutical Design
Title:The Role of Exosomes and Exosome-derived microRNAs in Atherosclerosis
Volume: 23 Issue: 40
Author(s): Xinjie Lu*
Affiliation:
- The Mary and Garry Weston Molecular Immunology Laboratory, Thrombosis Research Institute, London, SW3 6LR,United Kingdom
Keywords: Atherosclerosis, exosome, microRNA, MMP, CVD, vesicles.
Abstract: Background: Atherosclerosis is the leading cause of death and morbidity throughout industrialized nations, accounting for one-fifth of all deaths globally. Exosomes are bi-lipid membranous vesicles containing protein, lipid and nucleic acid contents that are released from the cells via the endolysosomal pathway. Exosomes are derived from several cells including macrophages, dendritic cells, platelets as well as human serum.
Methods: In this review, an overview of recent advances, the evidence for the role of exosomes and exosomederived microRNAs (miRNAs) in atherosclerosis are provided.
Results: Recent evidence has shown that exosomes derived from the cells mentioned above are involved in atherosclerosis, whose secretion appears to be regulated by various natural and experimental stimuli, physiological and pathological processes.
Conclusion: Exosomes are now accepted as specifically secreted vesicles that enable intercellular communications and have become exponentially interesting to be used as the possible relevant biomarkers in disease development such as cadiovascular disease, particular in atherosclerosis in addition to their minimally invasive clinical diagnosis.
Export Options
About this article
Cite this article as:
Lu Xinjie *, The Role of Exosomes and Exosome-derived microRNAs in Atherosclerosis, Current Pharmaceutical Design 2017; 23 (40) . https://dx.doi.org/10.2174/1381612823666170413125507
DOI https://dx.doi.org/10.2174/1381612823666170413125507 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers of Alcohol Consumption in Body Fluids - Possibilities and Limitations of Application in Toxicological Analysis
Current Medicinal Chemistry Levosimendan for Heart-Operated Patients: What is the State of the Art?
Recent Patents on Cardiovascular Drug Discovery Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Editorial [Hot Topic: Cardiac Cell Therapy: anno 2011 (Executive Guest Editor: Sophie Van Linthout)
Current Pharmaceutical Design Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry Increased Severity of Acute Cerebral Ischemic Injury Correlates with Enhanced Stem Cell Induction as well as with Predictive Behavioral Profiling
Current Neurovascular Research Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Bacterial Proteases in Disease – Role in Intracellular Survival, Evasion of Coagulation/ Fibrinolysis Innate Defenses, Toxicoses and Viral Infections
Current Pharmaceutical Design Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology The Impact of Hypertension in Hemodialysis Patients
Current Hypertension Reviews Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings
Current Molecular Pharmacology Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Colchicine in Renal Diseases: Present and Future
Current Pharmaceutical Design Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery